IDXX vs FERG vs ICCC Stock Comparison

Idexx Laboratories, Ferguson Enterprises and Immucell Prices as of Oct 28, 2026 Peers: Industry group
ICCC Immucell Corp /De/
$10.62 +7.5% 1M +72.4% 1Y
Market cap
$95.81M
P/E
–
Revenue (TTM)
$26.76M
Div. yield
–
Animal Health Healthcare
2 wins

Head to Head

11 decided of 12

Ferguson Enterprises leads on 5 of the 12 questions below (Ferguson Enterprises 5, Idexx Laboratories 4, Immucell 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionIDXXFERGICCCLeader
Larger companyMarket capitalisation $45.24B $46.16B $95.81M FERG
Cheaper on earningsLower P/E, profitable companies only 39.7x 22.8x -146.9x FERG
Cheaper on forward earningsLower price / next fiscal year consensus EPS 36.0x 21.6x — FERG
Faster revenue growthRevenue growth, trailing twelve months +12.8% +5.2% -5.3% IDXX
More profitableNet margin, trailing twelve months 25.0% 6.5% -2.4% IDXX
Better return on capitalReturn on invested capital 45.6% 21.7% 6.5% IDXX
Less leveragedLower net debt / EBITDA 0.5x 1.0x -0.1x ICCC
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -11.3% -6.6% +72.4% ICCC
Better 5-year returnAnnualised price return, 5 years -3.3%/yr +8.8%/yr +3.8%/yr FERG
Less volatileAnnualised volatility, 1 year 32.0% 29.8% 50.5% FERG
Higher overall scoreMean of the five percentile scores vs peers 78/100 66/100 73/100 IDXX

Percentile Scorecard

IDXXFERGICCC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisIDXXFERGICCC
Valuation 75 #155 of 625 42 #27 of 46 86 #86 of 625
Growth 76 #147 of 602 76 #10 of 39 65 #209 of 602
Profitability 97 #18 of 549 87 #6 of 39 83 #92 of 549
Financial Health 46 #351 of 654 50 #24 of 47 58 #277 of 654
Shareholder Returns 93 #26 of 367 74 #9 of 32 –
Overall 78 66 73
  • IDXX ranked among 672 companies in Pharmaceuticals and Biotechnology
  • FERG ranked among 49 companies in Distribution and Rental
  • ICCC ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodIDXXFERGICCCSPY
1 month +6.4%+1.5%+7.5% +0.9%
3 months -1.2%+2.0%-3.5% +5.9%
6 months +1.7%-9.9%+25.8% +8.5%
Year to date -16.8%+3.7%+72.7% +13.3%
1 year -11.3%-6.6%+72.4% +12.4%
3 years +43.8%+52.1%+123.1% +88.1%
3 years, per year +12.9%+15.0%+30.7% +23.5%
5 years -15.5%+52.6%+20.7% +68.2%
5 years, per year -3.3%+8.8%+3.8% +11.0%
10 years +435.8%+335.4%+88.6% +263.4%
10 years, per year +18.3%+15.9%+6.6% +13.8%

Risk

MeasureIDXXFERGICCCSPY
Volatility, 1Y 32.0%29.8%50.5% 12.7%
Downside volatility, 1Y 31.2%30.9%47.5% 12.7%
Beta vs S&P 500, 1Y 0.801.130.40 1.00
Return / volatility, 1Y -0.35-0.221.43 0.98
Max drawdown, 5Y -51.3%-43.6%-67.0% -25.4%
From 52-week high -26.6%-13.8%-9.4% -0.9%
52-week high $766.68$267.71$11.72 $779.14
52-week low $504.70$214.24$4.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleIDXXFERGICCC
P/E now vs peer median 39.0xmedian 17.4x 22.1xmedian 25.6x -147.6xmedian 17.4x
P/S now vs peer median 9.8xmedian 9.1x 1.4xmedian 1.1x 3.6xmedian 9.1x
EV/EBITDA now vs peer median 28.0xmedian 17.1x 15.1xmedian 13.3x 18.8xmedian 17.1x
P/FCF now vs peer median 35.4xmedian 19.0x 19.8xmedian 22.0x —median 19.0x
P/B now vs peer median 27.5xmedian 2.2x 7.6xmedian 2.6x 3.1xmedian 2.2x
PEG now vs peer median 2.58median 0.34 —median 2.36 -2.69median 0.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsIDXXFERGICCC
Revenue $4.55B $31.35B $26.76M
Gross profit $2.84B $9.73B $10.53M
Operating income $1.46B $2.82B $2.47M
Net income $1.14B $2.03B -$652.35K
Free cash flow $1.25B $2.26B –
R&D $261.47M – $2.40M
EPS (diluted) $14.37 $10.42 $-0.07
Cash & equivalents $196.93M $820.00M $8.86M
Total debt $968.86M $4.13B $8.30M
Shares (diluted) 79.31M 194.80M 9.19M
Enterprise value $44.45B $43.38B $73.26M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricIDXXFERGICCC
P/E 39.0x 22.1x -147.6x
P/FCF 35.4x 19.8x –
P/Operating cash flow 32.4x 17.1x –
P/S 9.8x 1.4x 3.6x
P/B 27.5x 7.6x 3.1x
P/Tangible book 29.3x 8.6x 3.1x
EV/EBITDA 28.0x 15.1x 18.8x
EV/EBIT 31.0x 17.1x 38.9x
EV/Revenue 9.9x 1.5x 3.6x
EV/FCF 36.0x 21.2x –
EV/Operating cash flow 32.9x 18.4x –
PEG (3Y EPS CAGR) 2.58 – -2.69

Growth

14 metrics
MetricIDXXFERGICCC
Revenue growth (1Y) 12.8% 5.2% -5.3%
Revenue CAGR (3Y) 9.0% – 19.5%
Gross profit growth (1Y) 14.4% 7.5% -0.6%
Gross profit CAGR (3Y) 10.5% – 36.0%
Operating income growth (1Y) 16.2% 17.6% 42.3%
Operating income CAGR (3Y) 11.7% – 34.3%
Net income growth (1Y) 15.6% 31.6% -137.0%
Net income CAGR (3Y) 12.9% – 52.3%
EPS growth (1Y) 18.1% 34.4% -136.4%
EPS CAGR (3Y) 15.1% – 55.0%
Operating cash flow growth (1Y) 51.4% 35.9% –
Operating cash flow CAGR (3Y) 22.5% – –
Free cash flow growth (1Y) 59.9% 42.8% –
Free cash flow CAGR (3Y) 28.4% – –

Profitability

14 metrics
MetricIDXXFERGICCC
Gross margin 62.4% 31.0% 39.3%
EBITDA margin 35.4% 10.2% 19.0%
Operating margin 32.0% 9.0% 9.2%
Pretax margin 31.3% 8.3% -2.2%
Net margin 25.0% 6.5% -2.4%
FCF margin 27.5% 7.2% –
Operating cash flow margin 30.1% 8.3% –
Return on equity 71.9% 34.0% -2.2%
Return on assets 33.4% 11.4% -1.5%
Return on invested capital 45.6% 21.7% 6.5%
Return on capital employed 68.6% 23.4% 6.1%
Asset turnover 1.3x 1.8x 0.6x
Cash conversion (OCF / net income) 1.2x 1.3x –
Stock comp / revenue 1.4% 0.3% 1.8%

Financial Health

11 metrics
MetricIDXXFERGICCC
Debt / assets 28.1% 23.2% 17.8%
Debt / equity 0.6x 0.7x 0.3x
Net debt / EBITDA 0.5x 1.0x -0.1x
Debt / FCF 0.8x 1.8x –
Liabilities / assets 53.2% 67.0% 32.7%
Equity / assets 46.8% 33.0% 67.3%
Interest coverage 38.6x – 5.3x
Current ratio 1.2x 1.8x 4.8x
Quick ratio 0.7x 0.8x 2.7x
Cash ratio 0.2x 0.1x 2.0x
Altman Z-score 20.21 5.42 4.63

Shareholder Returns

7 metrics
MetricIDXXFERGICCC
Dividend yield – 1.5% –
Net buyback yield 2.4% 1.9% –
Shareholder yield 2.4% 3.4% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusIDXXFERGICCC
Forward P/E 36.0xFY2026 21.6xFY2026 –
EPS, next fiscal year $15.63FY2026 $10.68FY2026 –
EPS growth, next FY +19.5%FY2026 +7.4%FY2026 –
EPS growth, the year after +12.9% +20.5% –
Revenue, next fiscal year $5.00BFY2026 $34.30BFY2026 –
Revenue growth, next FY +16.3%FY2026 +11.5%FY2026 –
Revenue growth, the year after +0.6% -0.7% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersIDXXFERGICCC
Held by institutions 93.6% 96.3% 15.0%
Institutions holding 1,289 937 32
Change in shares held, QoQ +4.1% +2.1% -2.6%
Institutions buying 587 477 15
Institutions selling 496 343 7
Buyers to sellers 1.18 1.39 2.14

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

IDXXFERGICCC
IDXX 1.00 0.34 0.06
FERG 0.34 1.00 0.05
ICCC 0.06 0.05 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, IDXX, FERG and ICCC?

Ferguson Enterprises (FERG) is the largest by market capitalisation: Idexx Laboratories (IDXX) $45.24B, Ferguson Enterprises (FERG) $46.16B, Immucell (ICCC) $95.81M.

Which stock is cheaper, IDXX, FERG and ICCC?

Ferguson Enterprises (FERG) trades on the lowest price-to-earnings ratio (Idexx Laboratories (IDXX) 39.7x, Ferguson Enterprises (FERG) 22.8x, Immucell (ICCC) -146.9x). On next year's consensus earnings, Ferguson Enterprises (FERG) is cheapest (Idexx Laboratories (IDXX) 36.0x, Ferguson Enterprises (FERG) 21.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Idexx Laboratories (IDXX) grew revenue fastest over the trailing twelve months: Idexx Laboratories (IDXX) +12.8%, Ferguson Enterprises (FERG) +5.2%, Immucell (ICCC) -5.3%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Idexx Laboratories (IDXX) 25.0%, Ferguson Enterprises (FERG) 6.5%, Immucell (ICCC) -2.4%). On return on invested capital, Idexx Laboratories (IDXX) leads (Idexx Laboratories (IDXX) 45.6%, Ferguson Enterprises (FERG) 21.7%, Immucell (ICCC) 6.5%).

Which stock has performed better?

Over the past year Immucell (ICCC) returned the most: Idexx Laboratories (IDXX) -11.3%, Ferguson Enterprises (FERG) -6.6%, Immucell (ICCC) +72.4%. Over five years, Ferguson Enterprises (FERG) compounded fastest (Idexx Laboratories (IDXX) -3.3%/yr, Ferguson Enterprises (FERG) +8.8%/yr, Immucell (ICCC) +3.8%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Ferguson Enterprises (FERG) has been the steadiest (Idexx Laboratories (IDXX) 32.0%, Ferguson Enterprises (FERG) 29.8%, Immucell (ICCC) 50.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, IDXX, FERG and ICCC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Ferguson Enterprises (FERG) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.